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Abstract
Background: Angiogenesis is the formation of neovasculature from a pre-existing vascular network. Progression of
solid tumors including lung cancer is angiogenesis-dependent. We previously introduced a bioinformatics-based
methodology to identify endogenous anti-angiogenic peptide sequences, and validated these predictions in vitro
in human umbilical vein endothelial cell (HUVEC) proliferation and migration assays.
Methods: One family of peptides with high activity is derived from the a-fibrils of type IV collagen. Based on the
results from the in vitro screening, we have evaluated the ability of a 20 amino acid peptide derived from the a5
fibril of type IV collagen, pentastatin-1, to suppress vessel growth in an angioreactor-based directed in vivo
angiogenesis assay (DIVAA). In addition, pentastatin-1 suppressed tumor growth with intraperitoneal peptide
administration in a small cell lung cancer (SCLC) xenograft model in nude mice using the NCI-H82 human cancer
cell line.
Results: Pentastatin-1 decreased the invasion of vessels into angioreactors in vivo in a dose dependent manner.
The peptide also decreased the rate of tumor growth and microvascular density in vivo in a small cell lung cancer
xenograft model.
Conclusions: The peptide treatment significantly decreased the invasion of microvessels in angioreactors and the
rate of tumor growth in the xenograft model, indicating potential treatment for angiogenesis-dependent disease,
and for translational development as a therapeutic agent for lung cancer.
Background
Judah Folkman pioneered the field of tumor angiogen-
esis by demonstrating that solid tumors are dependent
on their blood supply to grow and metastasize, thus pla-
cing the field of tumor angiogenesis at the center of
cancer biology and therapeutics [1]. Lung cancer is
responsible for the highest percentage of cancer deaths
(~28%) in both men and women worldwide [2]. The
number of annual deaths is over 160,000 in the United
States, and annually there are over 215,000 newly diag-
nosed cases [3]. Angiogenesis has been well documented
to play a role in lung cancer development and
progression [4-6]. Clinical evidence of angiogenesis in
lung cancer is abundant, manifested as an increase in
intratumoral microvascular density [7]. The over-expres-
sion of vascular endothelial growth factor (VEGF) has
also been correlated with rapid small cell lung cancer
(SCLC) growth [8]. Although SCLC makes up only 20%
of lung cancer cases, its characteristics have been
described as extremely virulent - correlated with rapid
cell growth, high resistance to chemotherapy, and low
median survival [9]. These factors correlate with a
shorter relapse-free and overall survival, indicating the
necessity for comprehensive treatment.
We recently developed a bioinformatics-based
approach to predict over 100 novel endogenous anti-
angiogenic peptides [10]. An important class of peptides
determined by this method was derived from the aIV,
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statins, pentastatins, and hexastatins, respectively. The
bioinformatics predictions were validated in vitro in cell
proliferation and migration assays on human umbilical
vein endothelial cells (HUVECs) [11]. Most peptides
showed a significant degree of anti-angiogenic activity;
the 20-mer peptide pentastatin-1 derived from aV fibrils
demonstrated high activity in both cell proliferation and
migration experiments. Based on these results we
applied pentastatin-1 to an angioreactor-based directed
in vivo angiogenesis assay (DIVAA), and to an in vivo
NCI-H82 SCLC xenograft model. We demonstrate high
activity in each of these assays, in addition to directly
inhibiting proliferation of NCI-H82 SCLC cells and 3T3
fibroblasts in vitro, indicating strong potential for pen-
tastatin-1 as a therapeutic agent for lung cancer.
Methods
Peptide synthesis and handling
The peptide pentastatin-1 (LRRFSTMPFMFCNINNVCNF)
was synthesized using a solid-phase synthesis technique by
a commercial provider (Abgent, San Diego, CA). The
endogenous human and mouse sequences are identical for
this peptide. The manufacturer provided HPLC and mass
spectrometry analysis to guarantee >95% purity. The pep-
tides were stored at -80°C in lyophilized form. Since pen-
tastatin-1 is hydrophobic, it was solubilized using 10%
dimethyl sulfoxide (DMSO) and water without any demon-
s t r a t e de f f e c to nc e l lv i a b i l i t y .
WST-1 cell viability experiments
In vitro viability assays were completed with pentastatin-
1 on NCI-H82 small cell lung cancer and mouse 3T3
fibroblast cell lines. NCI-H82 human SCLC cells were
obtained from the laboratory of Dr. D. Neil Watkins
(JHMI, Oncology). The cells were propagated in RPMI
1640 cell medium (Invitrogen, Carlsbad, CA) supple-
mented with 10% v/v fetal bovine serum, 10 mM of
HEPES, 2 mM of L-glutamine, 1% v/v of pen/strep, 1.5
g/l of sodium bicarbonate, and 1 mM of sodium pyru-
vate. The cells do not attach to the flask, but grow in
small floating colonies and are passaged by centrifuga-
tion (1,000 RPM, 5 min) without trypsinization and sub-
sequently resuspended in fresh media. 3T3 mouse
fibroblast cells were acquired from ATCC (Manassas,
VA) and grown under standard conditions in Dulbecco’s
Modified Eagle Medium (DMEM) (ATCC) with 10%
FBS and 1% pen/strep.
The effects of the peptide on the NCI-H82 and 3T3
cell viability were measured using the colorimetric cell
proliferation reagent WST-1 (Roche, Indianapolis, IN).
Approximately 2 × 10
3 cells were seeded per well in a
96-well microplate, centrifuged at 1,000 RPM for 5 min-
utes, and exposed for 3 days to peptide concentrations
o f :3 . 2 ,6 . 3 ,1 2 . 5 ,2 5 ,5 0 ,a n d1 0 0μg/mL. Cells were
tested in triplicate for each concentration. Microplates
containing NCI-H82s were centrifuged at 1,000 RPM
for 5 minutes to minimize loss of non-adherent cells
before application of WST-1. As an experimental con-
trol, equivalent to normal cell viability, the cells were
cultured without any agent in complete medium, con-
taining growth factors and serum without any exposure
to peptide.
BrdU cell proliferation assay
Cell proliferation was measured by BrdU (5-bromo-2’-
deoxyuridine) incorporation assay (Calbiochem/Merck,
Whitehouse Station, NJ) on both NCI-H82 cells and
3T3 fibroblasts according to manufacturer’s recommen-
dations. Briefly, 10,000 cells/well were plated into 96
well plates in the presence of pentastatin-1 at 3.8, 15,
and 60 μg/mL, and BrdU label (1:2000 dilution) for 24
hours. Plates were then washed, fixed with anti-BrdU
antibody, and peroxidase goat anti-mouse IgG conju-
gate. Immunocomplex formation was measured using
tetra-methylbenzidine solution, and the reaction termi-
nated using 2.5 N sulfuric acid. The measured intensity
is proportional to the amount of incorporated BrdU in
the cells. Absorbance was measured at 450 nm using a
Victor 3 V plate reader (PerkinElmer, Waltham, MA).
Cells were tested at five wells per concentration.
Directed in vivo angiogenesis assay (DIVAA)
DIVAA (Trevigen, Gaithersburg, MD) is a quantitative
in vivo method of assaying angiogenesis. Silicone cylin-
ders of 20 μlv o l u m ea n d1 0 0μm of inner diameter
(angioreactors) were closed on one side, and filled with
an extract of extracellular matrix containing VEGF and
fibroblast growth factor (FGF) with or without premixed
peptides as a control. These angioreactors were then
implanted subcutaneously in the abdominal region of
C57BL/6 mice, two angioreactors per animal, ventrally
one per each side of the peritoneal cavity. Capillary
sprouts originating from the host vessels invaded the
extracellular matrix and formed vessels in the angioreac-
tor. 12 days after the implantation, the mice were eutha-
nized and angioreactors were removed. The extracellular
matrix, containing the developed vasculature, was
removed from the cylinder and endothelial cells were
stained using FITC-Lectin, quantified by fluorescence at
510 nm emission with 485 nm excitation using a fluor-
escence plate reader (Victor 3 V, Perkin Elmer, Wal-
tham, MA). The intensity of the signal is proportional
to the number of endothelial cells contained in each of
the angioreactors. The results were normalized to the
mean of the experimental controls. Statistical signifi-
cance was tested by the Student’s t-test at p < 0.05 *.
In vivo tumor xenograft model
Animal protocols were approved by the Animal Care
and Use Committee at the Johns Hopkins Medical Insti-
tutions. Athymic nude mice were obtained from Harlan
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Page 2 of 7(Indianapolis, IN). The mice were 4-6 weeks of age and
housed on a 12 hour light dark cycle with food and
water provided ad lib. All mice were fed with a standard
caloric diet for their age.
Mice were allowed to acclimate for one week prior to
inoculation with NCI-H82 cells. NCI-H82 cells were
grown under the same conditions for in vitro cell viabi-
lity experiments. Prior to inoculation, the cells were pre-
pared in a solution containing 1:1 mixture of PBS and
Matrigel (BD Biosciences, San Jose, CA). 1 × 10
6 cells in
200 μl volume were injected subcutaneously in the right
flank area of the mice. Tumors were inspected 5 to 6
days after inoculation. The tumor inoculation efficiency
was approximately 75%.
Following growth incubation of 6-7 days, tumor size
volume was estimated by measurement of tumor dimen-
sions with digital calipers, and peptides were adminis-
tered once per day for 12 days, intraperitoneally (i.p), at 5
mg/kg and 10 mg/kg. In most cases the initial tumor
volume ranged from 150 mm
3 to 200 mm
3.E q u i v a l e n t
volumes of 10% DMSO in water were injected as an
experimental control. Separate controls of scrambled
peptide sequences were also made to test that the anti-
angiogenic efficacy of pentastatin-1 was sequence-depen-
dent. The injections were continued for 12 days, with a
total of 8 animals per group used for the experiments per
peptide per concentration. The location and side of the
injection were alternated every day. The higher dose of
10 mg/kg was repeated twice with similar tumor suppres-
sion and without a statistically significant change.
The tumor dimensions were measured every three
days. We measured two dimensions for each tumor, a
long and short axis. In some cases the tumors developed
as two lobes, in which we considered the whole tumor
as a single lobe with two associated axes. In order to
estimate the volume we considered the tumors as pro-
late spheroids with volume equal to (4/3)πab
2,w h e r ea
is the measurement for the long semi-axis and b is the
measurement for the short semi-axis.
Statistical analysis
The average tumor size per condition and the standard
error of the mean are reported over time. The statistical
significance measured using the Student’s t-test with sig-
nificance defined at p <0 . 0 5*a n dp < 0.01 **. Statistical
significance was tested among the peptide condition and
the experimental control in addition to the scrambled
peptide.
Immunohistochemistry
Immediately following the sacrifice of the mice, tumors
were excised and stored in a zinc-based fixative (BD Bios-
ciences, San Jose, CA) for 10-14 days, and sent to the
JHMI Immunohistochemistry Core Facility for paraffin
wax-embedding and processing. After deparaffinization
and rehydration, 5 μm cross sections were treated
overnight at room temperature with a monoclonal rat
anti-mouse CD31 (PECAM-1) IgG antibody (1:100) (BD
Pharmingen, San Jose, CA), which specifically recognizes
an epitope on the surface of endothelial cells. Secondary
antibody incubation was made using biotinylated rabbit
anti-rat IgG antibody (1:200) for one hour, and lightly
counterstained with hematoxylin.
Similar analysis was made for the apoptotic marker
cleaved (activated) caspase-3. After deparaffinization and
rehydration of slides, primary antibodies were applied at
dilutions of 1:400 for cleaved caspase-3 (rabbit polyclo-
nal antibody; Cell Signaling Tech., Boston, MA, Cat.
#9661), diluted in antibody dilution buffer (ChemMat,
S a nD i m a s ,C A ,C a t . # A D B 2 5 0 )a n di n c u b a t e da t1 4
hours at 4°C. Primary antibodies were detected using
the Power Vision Plus HRP-polymer detection system
(Leica Microsystems, Bannockburn, IL, Cat.#PV6119)
per manufacturer’s instructions. DAB chromogen
(Sigma Chemicals, St. Louis, MO, Cat.#D4293) was
applied to develop the secondary detection reagent.
Slides were counterstained with hematoxylin and
mounted on cover slips.
All histological samples were digitized, then processed
using Aperio Image Scope Software (Aperio Technolo-
g i e sI n c . ,V i s t a ,C A ) ,a n dq u a n t i f i e du s i n gF R i D As o f t -
ware (Johns Hopkins University, Baltimore, MD). For
the CD31 antibody staining 100% represents the mean
of the experimental controls. Apoptotic cell counts were
made per frame at 20× magnification using FriDA. Each
peptide concentration was compared to the control and
scrambled peptide equivalent using the Student’s t-test
at p < 0.05 * and p < 0.01 **.
Results
In vitro cell viability experiments show pentastatin-1
decreases NCI-H82 SCLC and 3T3 fibroblast viability at
increasing concentrations (Fig. 1A). Pentastatin-1
decreases NCI-H82 cell viability by 26% at 25 μg/mL,
and to a maximum decrease of 42% at 100 μg/mL in
comparison to the untreated controls. The effect on 3T3
fibroblasts is significant with a decrease of 20% at 25 μg/
mL, and a maximum effect of an 81% decrease on cell
viability at 100 μg/mL measured by the WST-1 colori-
metric reagent. There is a statistically significant differ-
ence from the control beginning at concentrations of
25, 50, and 100 μg/mL for NCI-H82 SCLC, and 50 and
100 μg/mL for 3T3 fibroblasts. Similarly, we show that
pentastatin-1 inhibits cell proliferation through DNA
synthesis by incorporation of BrdU label (Fig. 1B). Upon
incubation of peptide for one day, pentastatin-1 inhibits
proliferation by 50% for NCI-H82 and 33% for 3T3
fibroblasts at 60 μg/mL.
We show the application of pentastatin-1 in two in
vivo angiogenesis assays. Fig. 2 shows the results of the
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the angioreactors containing the peptide (Fig. 2A),
shown for the control and the highest peptide concen-
tration of 200 μg/mL. The percent vascularization of
the tubes decreases with increasing peptide concentra-
t i o n ,s h o w ni nF i g .2 B .A t3 0μg/mL the vasculariza-
tion decreases by 19%, and this trend continues to a
67% decrease for 50 μg/mL, and an 88% decrease at
200 μg/mL in comparison to the experimental control.
Results are statistically lower from the control at p <
0.05 beginning at concentrations of 30 μg/mL.
In the tumor xenograft experiment we follow the
mean tumor volume of pentastatin-1 treated xenografts
(Fig. 3A), along with the experimental control and
scrambled peptide over time for two doses of 5 mg/kg
and 10 mg/kg. The control tumors grow rapidly to a
final mean volume of 1,235 mm
3 on day 12. The lower
dose of 5 mg/kg statistically suppresses tumor growth
by 20% by day 12 (Fig. 3B). Beginning on day 4 the
average tumor volume of the 10 mg/kg is statistically
lower than the experimental control, and this signifi-
cance was maintained until the termination of the
Figure 1 In vitro cell viability assay. A. NCI-H82 small cell lung
cancer cells (H82) and 3T3 fibroblasts (3T3) were plated at 2,000
cells/well. Pentastatin-1 peptide was applied at increasing
concentrations up to 100 μg/mL, and incubated for three days. Cell
viability was determined using the WST-1 colorimetric agent, and
scaled to the untreated experimental control. Differences between
H82 and 3T3 treatments are statistically significant as determined by
the Student’s t-test at p < 0.05 * and p < 0.01 **. B. BrdU
incorporation for NCI-H82 small cell lung cancer cells and 3T3
fibroblasts. Cells were plated at 10,000 cells/well with pentastatin-1
at concentrations of 3.8, 15 and 60 μg/mL in the presence of a
BrdU label for 24 hours. BrdU incorporation was detected by the
BrdU-antibody peroxidase conjugate as a measurement for cell
proliferation by DNA synthesis. Pentastatin-1 decreases cell
proliferation by 50% for H82 and 33% for 3T3 at 60 μg/mL.
Statistical significance is determined at p < 0.05 * and p < 0.01 **
by Student’s t-test.
Figure 2 angioreactor-based in vivo assay. A.D i r e c t e din vivo
angiogenesis assay (DIVAA) showing silicone tubes with and
without application of pentastatin-1 at 200 μg/mL. Angioreactors
were implanted subcutaneously into the abdominal region of
C57BL/6 mice for 12 days, and vessels allowed to infiltrate. B.
Peptides were mixed at concentrations of 30, 50, 100, and 200 μg/
mL with Matrigel (BD Biosciences, San Jose, CA), and vascularization
assayed and scaled where 100% represents the mean of the
untreated controls (Ctrl). Results are significantly less than controls
at p < 0.05 *.
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increases the suppression of the tumor more than the 5
mg/kg concentration to a 53% inhibition by day 12. The
scrambled peptide is used to verify the correlation
between amino acid content and tumor suppression is
sequence-dependent, and is not statistically different
from the control tumors at any point in the experiment
(data not shown). The percent inhibition for each condi-
tion over the 12 days for the experiment is summarized
in Fig. 3B. Experiments were terminated on day 12 as
the controls had reached maximum values outlined in
the ethical care and use protocol.
Fig. 4A shows the effect of pentastatin-1 on the
microvascular density of the tumors, visually, as CD31 is
a marker for endothelial cells. Similar caspase-3 immu-
nohistochemistry reveals the presence of apoptotic cells
within the tumor microenvironment. The experimental
control contains more vessels than the peptide-treated
tumors, and this is verified quantitatively in Fig. 4B.
Both concentrations at 5 mg/kg and 10 mg/kg are statis-
tically different from the experimental control, showing
a 23% decrease for 5 mg/kg and 24% decrease for 10
mg/kg in vasculature compared to the control. The
scrambled peptide is not statistically different from the
control, but is different from the peptide-treated tumors.
Fig. 4C shows the number of apoptotic cells per frame
at 20× for the PBS-treated controls, and pentastatin-1 at
5 mg/kg and 10 mg/kg. Controls contained a mean
number of 7 apoptotic cells/frame, while pentastatin-1
contained 19 and 22 apoptotic cells/frame at 5 mg/kg
and 10 mg/kg, respectively.
Discussion
Currently, there is a high unmet need for treatment of
small cell lung cancer as upwards of 95% of patients
diagnosed with the disease will die within five years [9].
A number of pharmaceutical agents are in clinical trials
for SCLC [12], e.g. tyrosine kinase inhibitors imatinib
(Gleevec, Novartis, East Hanover, NJ), and gefitinib
(Iressa, AstraZeneca, Wilmington, DE), along with the
anti-VEGF antibody agent bevacizumab (Avastin, Gen-
entech/Roche, San Francisco, CA) [13]. Although pep-
tide-based therapies have development obstacles to
overcome such as short in vivo half-lives and degrada-
tion by proteases, they are also advantageous due to low
toxicities, high selectivity, and potential to enhance
existing cytotoxic therapies [14].
Collagen IV forms the bulk of the structure of the vas-
cular basement membrane, and is known to contain sev-
eral cryptic fragments with anti-angiogenic activity [15].
Several collagen-derived peptides are being tested in
pre-clinical models such as tumstatin [16] and celingi-
tide in glioblastoma [17]. We have shown that pentasta-
tin-1, a collagen IV derived 20-mer peptide, is effective
in a preclinical model of SCLC. The high potency of
pentastatin-1 in the disease-independent DIVAA assay
shows a strong potential for application to various
angiogenesis-dependent disease models, including can-
cer. The suppression of tumor growth in the SCLC
xenograft demonstrates specific application to lung can-
cer, and potential for clinical development.
We have previously shown pentastatin-1 decreases
HUVEC migration and viability in vitro. Similarly, we
show pentastatin-1 effectively inhibits viability of NCI-
H82-SCLC cells and 3T3 fibroblasts by WST-1 colori-
metric agent, and inhibits synthesis of DNA by BrdU
incorporation indicating the peptide targets multiple
cell types in addition to being anti-angiogenic. Pre-
viously published xenograft work shows pentastatin-1
has low toxicity measured by H&E staining of vital
organs in severe combined immunodeficient (SCID)
mice [18]. We have also shown that pentastatin-1
Figure 3 NCI-H82 small cell lung cancer xenograft in nude
mice. A. Mean tumor volume reported over time for the NCI-H82
SCLC xenograft model. Peptides were administered intraperitoneally,
once per day, at two separate concentrations of 5 mg/kg or 10 mg/
kg in comparison to a PBS-treated control and a scrambled peptide
equivalent (not shown). Pentastatin-1 significantly suppressed
growth for all days at 10 mg/kg by Student’s t-test at p < 0.01 **
and demonstrated a dose response in vivo. B. Percent inhibition
from day 1 reported over time for pentastatin-1 at 5 mg/kg and 10
mg/kg.
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endothelial cells [10], and are also expressed on several
SCLC cell lines [19] including NCI-H82s [20], indicat-
ing likely targets for pentastatin-1 to bind on this cell
line.
In our xenograft model we show pentastatin-1 has a
monotonic dose response and suppresses tumor growth
at both 5 mg/kg and 10 mg/kg, while decreasing the
microvascular density and increasing apoptotic cell
count in response to the peptide application. At the
higher dose the peptide suppresses tumor growth signif-
icantly with an inhibition of 53%. Although the tumors
grow and reach a size larger than the initial size when
peptide was administered, the peptide still effectively
suppresses the tumor growth when used as monother-
apy. The scrambled peptide equivalent shows that the
peptide’s activity is sequence-dependent, as it is not sta-
tistically different from the control. The presence of b1
and b3 integrin receptors on endothelial cells is consis-
tent with the decrease in microvascular density, as the
peptide targets these receptors, while a lower microvas-
cular density is correlated with a decrease in tumor
development and growth.
Conclusions
Type IV collagen contains several cryptic fragments with
anti-angiogenic properties. We previously identified sev-
eral anti-angiogenic fragments through a bioinformatics-
based methodology, including pentastatin-1, which
showed high potency to in vitro HUVEC proliferation
and migration assays. Small cell lung cancer is very
resistant to chemotherapy, and has a high mortality rate
indicating the need for comprehensive treatment. The
disease has been shown to be angiogenesis-dependent.
Based on previous in vitro experiments, we selected pen-
tastatin-1 for application to the angioreactor-based
DIVAA, and a small cell lung cancer xenograft model
using nude mice. The peptide has shown to be effective
in a pre-clinical model for limiting tumor growth, and
has the potential for translational research in lung
cancer.
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